Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving sorafenib together with
tamoxifen and cisplatin after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying the side effects and how well giving sorafenib
together with tamoxifen and cisplatin works in treating patients with high-risk stage III
melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
San Diego Pacific Oncology & Hematology Associates